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INTRODUCTION
Latest reports showed that lung cancer remains 
the most common fatal malignancy among males in the 
world [1]. Approximately 80% of cases are non-small cell 
lung cancer (NSCLC), and majority of NSCLC patients 
present with symptoms in a late advanced stage [2]. 
Despite recent advances in chemotherapy, the outcome 
for individuals with NSCLC is extremely poor. Generally, 
5-year survival rate for lung cancer does not exceed 15% 
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ABSTRACT
Lung cancer is a serious health problem and the leading cause of cancer 
death worldwide, due to its high incidence and mortality. 85% of lung cancers are 
represented by the non-small cell lung cancer (NSCLC). Traditional chemotherapy has 
been the main treatment option in NSCLC. However, it is often associated with limited 
efficacy and overall poor patient survival. In recent years, molecular targeting has 
achieved great progress in therapeutic treatment of cancer and plays a crucial role in 
the current clinical treatment of NSCLC, due to enhanced efficacy on cancer tissues and 
reduced toxicity for normal tissues. In this review, we summarize the current targeting 
treatment of NSCLC, including inhibition of the epidermal growth factor receptor 
(EGFR), phosphatidylinositol 3-kinase (PI3Ks), mechanistic target of rapamycin 
(mTOR), epidermal growth factor receptor 2 (ErbB2), vascular epidermal growth 
factor receptor (VEGFR), kirsten human rat sarcoma protein (KRAS), mesenchymal-
epithelial transition factor or hepatocyte growth factor receptor (c-MET), anaplastic 
lymphoma kinase (ALK), v-Raf murine sarcoma viral oncogene homolog B (BRAF). This 
article may serve as a guide to clinicians and researchers alike by assisting in making 
therapeutic decisions. Challenges of acquired drug resistance targeted therapy and 
imminent newer treatment modalities against NSCLC are also discussed.
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 PFS (Progression-free Survival): the length of time during and after the treatment of a 
disease, such as cancer, that a patient lives with the disease but it does not get worse 
 OS (Overall Survival): the time from randomization to the date of death or the date of 
termination of the trial (for patients alive at the time end of the study), or the date of the last 
follow-up information available (for patients loss before the trial end date) 
 ORR (Objective Response Rate): the number of complete plus partial response divided by 
the total of patients enrolled in each comparison arm.
           Review
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[3]. Thus, novel treatment strategies based on targeted 
therapy and targeted compounds started to be developed 
and implemented by researchers and clinicians. Up to 
now, several anti-cancer drugs targeting epidermal growth 
factor receptor (EGFR), phosphatidylinositol 3-kinase 
(PI3Ks), mechanistic target of rapamycin (mTOR), 
epidermal growth factor receptor 2 (ErbB2), vascular 
epidermal growth factor receptor (VEGFR), kirsten human 
rat sarcoma protein (KRAS), mesenchymal-epithelial 
transition factor or hepatocyte growth factor receptor 
(c-MET), anaplastic lymphoma kinase (ALK), v-Raf 
murine sarcoma viral oncogene homolog B (BRAF) have 
been developed, with undergoing clinical trials (Figure 1). 
Genetic changes of other genes have been identified 
(Figure 2), but EGFR, ALK and KRAS mutations are the 
most frequent mutations in lung cancer. To some extent, 
most of these inhibitors have shown promising anti-tumor 
efficacy, causing a paradigm shift for the treatment of 
advanced NSCLC, although some serious side effects, such 
as nausea, vomiting, hair loss and fatigue have been found 
in clinical trials [4–6]. In this review, we outline the recent 
progresses along with the emerging obstacles in NSCLC 
therapy.
CHEMOTHERAPY
Cisplatin
Cisplatin, as a non-specific drug working on cell 
cycle, is one of the common chemotherapeutic drugs in 
clinic, and acts as an anti-tumor drug mainly through 
suppressing DNA replication [7]. Additionally, cisplatin 
has anticancer activity by damaging the cellular membrane 
[8]. In advanced NSCLC, patients receiving cisplatin-
based chemotherapy had shown significantly improved 
survival and quality of life along with many side-effects 
[9–11]. In a multinational, multicenter, open-label, phase 
III trial, 1125 patients with advanced NSCLC were 
randomly assigned to receive cisplatin alone and cisplatin 
plus cetuximab (an EGFR tyrosine kinase inhibitor). The 
results showed that patients survived longer in cisplatin 
plus cetuximab group than those in the cisplatin-alone 
Figure 1: Molecular targets in NSCLC. Various mechanisms including amplification and mutation may lead to activation of EGFR, 
PI3K, mTOR, HER2, KRAS, c-MET, ALK, BRAF and corresponding signaling pathways, while targeting inhibitors suppress the activation 
in NSCLC and result in therapeutic effects.
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group (median survival is 11.3 months versus 10.1 
months; hazard ratio (HR) for death: 0.87, p = 0.04). 
Grade 3 or 4 side effects (acne-like rash:10%; diarrhea: 
5%; infusion-related: 4%) were seen more in cisplatin 
plus cetuximab group [12]. In another phase II study, 39 
patients with advanced NSCLC were randomly assigned 
to receive pemetrexed (a DNA/RNA synthesis inhibitor)-
cisplatin (500 mg/m2, intravenously) concurrent with 
radiotherapy. The progression free survival (PFS) was 
11.8 months, median overall survival (OS) was 30.3 
months and time to progressive disease was 13.7 months. 
The response rate was approximately 46.0%. Grade 3 
to 4 side effects (hematologic and esophagitis) were 
observed in this study [13]. These observations suggest 
that although cisplatin and cisplatin-based combinations 
have significant anticancer effects in NSCLC treatment, 
many side effects are also observed in the same time.
Paclitaxel 
Paclitaxel, a novel anti-microtubule drug, 
functions as anti-cancer reagent through maintaining 
tubulin stabilization and inhibiting cell mitosis. Although 
the clinical study showed paclitaxel’s effect on ovarian 
cancers and breast cancers [14, 15], it has certain curative 
effect on lung cancer, colorectal cancer, melanoma, head 
and neck cancer, lymphoma, brain tumors as well [16]. In 
a phase Ш trail, 134 patients with advanced NSCLC were 
randomly assigned to two groups: paclitaxel at 15 mg/m2 
(three times/week for 6 weeks, n = 74) and paclitaxel at 
45 mg/m2 (weekly for 6 weeks, n = 60). Interestingly, the 
response rate for low-dose paclitaxel was significantly 
higher than high-dose paclitaxel (83.1% vs 54.2%, 
p = 0.001). Recurrence-free survival (RFS) in low-
dose paclitaxel group was also superior than in high-
dose paclitaxel group (14.6 months vs 9.4 months, 
HR = 1.87, 95% CI (confidence interval) = 1.20–2.90, 
p = 0.005). Serious toxicities including grade 3 and 4 
leukopenia/neutropenia were less occurred in low-
dose paclitaxel group (p < 0.001) [17]. Nevertheless, a 
large number of side effects, such as allergic reactions, 
myelosuppression, neurotoxicity, cardiovascular 
toxicity and gastrointestinal reactions, were observed 
in these paclitaxel clinical trials [18–20]. Herein, a 
growing number of clinical trials are now investigating 
if nanoparticle paclitaxel could be a better treatment 
option as an anti-NSCLC therapy, with lower side 
effects. In a randomized and placebo-controlled clinical 
study, 92 patients with advanced NSCLC, after first-line 
platinum based chemotherapy failure, were randomly 
assigned to receive nanoparticle albumin-bound 
paclitaxel (nab-paclitaxel) or placebo. The median 
PFS was longer in nab-paclitaxel than in placebo 
(4.6 months vs 2.0 months; HR = 0.62, 95% CI = 0.33–0.81, 
p < 0.001). The median OS was 6.3 months versus 
4.9 months in nab-paclitaxel and placebo, respectively 
(HR = 0.71; 95% CI = 0.33–0.85, p < 0.001). However, 
adverse events were also observed in nab-paclitaxel [21]. 
Similar to cisplatin and paclitaxel, nab-paclitaxel has 
anti-tumor efficacy with serious side effects [21].
TARGETED SMALL-MOLECULE 
INHIBITORS
EGFR mutation and EGFR tyrosine kinase 
inhibitors
EGFR mutation
Epidermal Growth Factor Receptor (EGFR, HER1) 
belongs to a family of ErbB receptors that includes 
ErbB-1, ErbB-2, ErbB-3 and ErbB-4, and is critical 
Figure 2: Occurrence of genetic changes in NSCLC. The frequency of different genetic changes occurred in NSCLC including 
EGFR, ALK, KRAS, HER2, BRAF, PI3KCA.
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for tumor development, metabolic and physiological 
processes [22]. EGFR mutations are most prevalent and 
well characterized in NSCLC [23]. Numerous studies 
have reported that EGFR mutations frequently occurred 
especially in substitution of arginine for leucine at amino 
acid position 858 (L858R) within exon 21, and an in-
frame deletion within exon 19 (delE746-A750) in NSCLC 
patients, which accounts for 85% of EGFR mutations 
[24–26]. NSCLC patients harboring EGFRL858R mutation 
have benefited from EGFR TKIs treatments [27–30]. 
However, most NSCLC patients initially responding to 
gefitinib and erlotinib eventually become resistance [31]. 
In some cases, the drug resistance is a result of a second 
point mutation in the TK domain, in which the point 
mutation threonine-to-methionine substitution at position 
790 (T790M) occurs in approximately one half of these 
acquired resistance cases [32]. 
EGFR-TKI 
Gefitinib
Gefitinib, the first generation of EGFR TKIs, was 
approved by Food and Drug Administration (FDA) in 
2003 as the second line drug for the treatment of patients 
with advanced NSCLC after failure of both platinum-
based and docetaxel therapies [33]. It has been newly 
approved by FDA as the first-line treatment of patients 
with metastatic NSCLC bearing EGFR exon 19 deletions 
or exon 21 (L858R) mutations in 2015 [33]. The post-hoc 
analyses of the phase III, randomized, multicenter, Iressa 
Pan-ASia Study (IPASS) study of 261 Asian patients (non-
smokers) with EGFR mutation-positive advanced NSCLC 
were randomly assigned to receive gefitinib (250 mg/day) 
versus carboplatin/paclitaxel [34]. The median PFS 
suggested a statistically significant improvement with 
gefitinib (10.9 months) versus carboplatin/paclitaxel 
(7.4 months; HR = 0.54, 95% CI = 0.38–0.79, p = 0.0012). 
The objective response rate (ORR) was significantly 
higher with gefitinib (67.0%) than with carboplatin/
paclitaxel (40.8%) (OR = 3.00; 95% CI = 1.63–5.54; 
p < 0.001). The median disease progression (DoR) 
was 9.6 months (95% CI = 7.4–12.5) and 5.5 months 
(95% CI = 4.1–5.7) in the gefitinib group and carboplatin/
paclitaxel group, respectively. Nevertheless, vomiting, 
nausea, diarrhea and interstitial lung disease have been 
observed in gefitinib group [34]. EGFR inhibition and/or 
drug off-targets effects might cause these adverse events 
[35]. Thus, to minimize the side effects, identification the 
off-targets of gefitinib may be an important task. Recently, 
by the systems biology based on silico analysis, the crystal 
structure of EGFR-gefitinib complex was used to identify 
off-targets of gefitinib through binding pocket similarity 
searches on a druggable proteome database (Sc-PDB) 
[36]. Besides EGFR, mitogen activated protein kinase 10 
(MAPK10), polymer of intrinsic microporosity-1 (PIM-1), 
dihydroorotate dehydrogenase (DHODH), epidermal 
growth factor receptor 4 (ERBB-4), 17β Hydroxysteroid 
dehydrogenase type 1 (HSD17B1), checkpoint kinase-2 
(CHK2) as well as checkpoint kinase-1 (CHK1) also 
efficiently binds gefitinib [36]. Although gefitinib has 
shown high efficacy in patients with advanced NSCLC, 
drug resistance is commonly acquired when associating 
with EGFR T790M. Gefitinib in combination with AT-
101 (a pan-Bcl-2 inhibitor) significantly inhibits cell 
proliferation, as well as promotes apoptosis of NSCLC 
cells involving blocking of B-cell lymphoma-2 (Bcl-2), 
B-cell lymphoma-xl (Bcl-xl), and myeloid cell leukemia-1 
(Mcl-1) and downregulating of EGFR signaling [37, 38]. 
Animal studies further supported that the combination of 
gefitinib with AT-101 reinforces efficacy in NSCLC with 
EGFR T790M mutations [38].
Erlotinib
Erlotinib is another first-generation TKI that 
reversibly binds to EGFR approved by FDA in 2004. In 
2013, it was approved by FDA as the first-line treatment 
for patients with metastatic NSCLC harboring EGFR exon 
19 deletions or exon 21 (L858R) mutations [39]. In an 
open-label, randomized, multicenter, phase II study, 154 
patients with advanced NSCLC with activating EGFR 
mutations randomly received erlotinib (150 mg/day) 
monotherapy or erlotinib (150 mg/day) plus bevacizumab 
(150 mg/kg) as a first-line therapy. The median PFS was 
16.0 months in the erlotinib plus bevacizumab group 
(95% CI = 13.9–18.1) and 9.7 months in the erlotinib 
alone group (HR = 0.54, 95% CI = 0.36–0.79, p = 0.0015) 
[40]. The most common grade 3 or worse adverse events 
were occurred with higher frequently in the erlotinib plus 
bevacizumab group than erlotinib alone group (25% vs 
19%). Frequency of serious adverse events (24% vs 25%) 
in both groups was similar [40].
Icotinib
Icotinib, an oral selective EGFR TKI, has been 
approved by the China Food and Drug Administration 
(CFDA). In a phase III non-inferiority trial in 27 hospitals 
in China, 400 advanced NSCLC patients not responding 
to platinum-based chemotherapy were treated with 
either gefitinib (250 mg/day) or icotinib (125 mg/tid). 
The median PFS was 4.6 months versus 3.4 months 
in icotinib group and gefitinib group, respectively 
(HR = 0.8, 95% CI = 0.7–1.1, p = 0.13), indicating that 
icotinib was non-inferior to gefitinib [41]. Drug-related 
adverse events, especially drug-related diarrhea (19% vs 
28%, p = 0.033), were less occurring in icotinib group, 
compared with patients receiving gefitinib (61% vs 70%, 
p = 0.046) [41]. Another study has also demonstrated 
higher efficacy and safety with icotinib for patients with 
advanced NSCLC after chemotherapy treatment. In this 
single-arm, multi-center, prospective study, 128 NSCLC 
patients after chemotherapy treatment were randomly 
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selected to receive icotinib (375 mg/day). The median 
PFS was 5.0 months (95% CI = 2.9–6.6) and time to 
progression was 5.4 months (95% CI = 3.1–7.9). The 
disease control rate and ORR were 67.7% and 25.8%, 
respectively. Rash (26%), diarrhea (12.6%) were seen in 
the icotinib treatment [42].
Afatinib
Afatinib is a second-generation EGFR TKI. It 
was approved by FDA in 2013 as a first-line treatment 
of patients with metastatic NSCLC bearing mutant 
EGFR (exon 19 deletions or exon 21 mutations) [43]. In 
randomized phase Ш trial based on 36 centers covering 
China, South Korea and Thailand, 910 Asian patients 
with advanced NSCLC were randomly assigned in three 
groups: afatinib (40 mg/day), gemcitabine (1000 mg/m²) 
and cisplatin (75 mg/m²). There was a significantly 
longer median PFS in afatinib group (11 months, 95% 
CI = 9.7–13.7) than that in either gemcitabine group 
or cisplatin group [44]. In another phase III study, 345 
patients with stage IIIB/IV lung adenocarcinoma of 
EGFR mutations (exon 19 deletion, L858R, or other) 
were randomly assigned to either afatinib (40 mg/day) or 
cisplatin plus pemetrexed. It was found that the median 
PFS of afatinib-treated patients harboring exon 19 deletions 
and EGFR L858R mutation was 13.6 months, much longer 
than the median PFS of cisplatin plus pemetrexed group 
(6.9 months, HR = 0.47, 95% CI = 0.34–0.65, p = 0.001) 
[45]. Diarrhea, rash/acne, and stomatitis were observed 
in afatinib, while nausea, fatigue, and decreased appetite 
were occurred in chemotherapy [45]. Additionally, afatinib 
as an effective first-line treatment drug has presented 
definite good results in advanced NSCLC patients with 
EGFR-mutations who had received erlotinib, gefitinib, or 
both before [46–48].
Dacomitinib
Dacomitinib is a second-generation, irreversible 
TKI of EGFR that shows efficacy in NSCLC patients 
both in initial treatment and after failing treatment of first-
generation inhibitors. The superiority of dacomitinib to 
its first generation TKI counterparts in advanced NSCLC 
was further characterized in a phase II trial: 66 patients 
with advanced NSCLC after failure of prior chemotherapy 
and erlotinib were randomly assigned to dacomitinib 
(45 mg/day). The median PFS was 12 weeks overall 
(n = 66) and 18 weeks (n = 26) for patients with EGFR 
mutation-positive tumors. Diarrhea, acneiform dermatitis, 
exfoliative rash, fatigue and stomatitis were observed in 
dacomitinib treatment. The results showed dacomitinib 
is preliminary activity and acceptable tolerability in 
heavily pretreated patients [49]. Clinical data showed 
dacomitinib has significant efficacy in advanced NSCLC 
patients with EGFR exon 19 deletion [50]. In the pooled 
subset analyses, two clinical trials were used to test 
the efficacy of dacomitinib in NSCLC. The ARCHER 
1009 (NCT01360554) and A7471028 (NCT00769067) 
studies randomly assigned advanced NSCLC patients to 
either dacomitinib or erlotinib, while EGFR alteration 
examination was performed centrally on archived 
tumor samples. The median PFS was 14.6 months with 
dacomitinib and 9.6 months with erlotinib (HR = 0.717, 
95% CI = 0.458–1.124; p = 0.146). The median survival 
was 26.6 months with dacomitinib versus 23.2 months 
with erlotinib (HR = 0.737, 95% CI = 0.43–1.259, 
p = 0.265) [50]. The results showed that dacomitinib 
has similar or better efficacy to erlotinib in patients with 
EGFR mutations. Interestingly, individuals with exon 19 
deletion have more favorable outcomes with dacomitinib 
than with erlotinib.
Osimertinib (AZD9291) 
Osimertinib is a third-generation TKI that binds 
to EGFR and was approved by FDA in 2015 for patients 
with metastatic EGFRT790M NSCLC progressing on or after 
EGFR TKI therapy. NSCLC patients harboring an EGFR-
activating mutation develop acquired resistance after a 
median of 9–11 months from the beginning of treatment 
with TKI, such as erlotinib and gefitinib [51, 52]. 
Osimertinib is a highly selective EGFR mutant inhibitor, 
which has been developed to be potent against EGFR 
mutations, including T790M mutation, while sparing 
wild-type EGFR [53, 54]. Dr. Jänne showed that in a group 
of 253 lung cancer patients with or without EGFRT790M 
mutation receiving osimertinib at a dose of 20–240 mg/day, 
the median PFS is much longer in EGFR T790M-positive 
patients than in EGFR T790M-negative patients (9.6 
months vs 2.8 months), suggesting that advanced NSCLC 
patients with the EGFRT790M mutation were extraordinary 
sensitive to osimertinib (95% CI = 8.3–not reached) [55]. 
Different technology platforms have been used to assess 
the sensitivity and specificity of osimertinib to patients 
with EGFRT790M mutation. Results showed that patients 
with EGFRT790M mutation possess high sensitivity and 
specificity to osimertinib [56]. All observations suggest 
that patients with T790M mutation or resistance to EGFR 
TKI could be benefited from osimertinib. 
CT16
CT16, targeting both EGFR and Notch2/3 receptors, 
not only inhibited signaling mediated by these receptors, 
but also showed a strong anti-stem cell effect both in 
vitro and in vivo. Data showed CT16 limits acquiring 
resistance to EGFR inhibitors and radiation in NSCLC cell 
line and patient-derived xenograft tumors. On the other 
hand, CT16 had a superior radio-sensitizing impact than 
other EGFR inhibitors [57]. These findings suggest that 
CT16 combining radiation may reveal clinical efficacy for 
patients with NSCLC.
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PI3KCA mutation and PI3Ks inhibitors 
PI3KCA mutation
Phosphatidylinositol 3-kinases (PI3Ks) closely 
associates with cell proliferation, survival, adhesion and 
neoplasia [58]. The mutation of phosphatidylinositol 
3-kinases catalytic alpha (PIK3CA) gene may play a 
role as an oncogene in human cancers [59], frequently 
occurring at exons 9 and 20 [60]. Mutant PIK3CA was 
found in approximately 4% NSCLC [60, 61].
PI3Ks inhibitors
PX-866
PX-866 is an irreversible, pan-isoform inhibitor of 
PI3Ks. Nathan et al. have shown that PX-866 improved 
the antitumor activity of gefitinib in A549 NSCLC 
xenografts [62]. However, the main results were divergent 
in a randomized, phase II trial: 95 patients with advanced, 
recurrent, or metastatic NSCLC randomly assigned 
to docetaxel (75 mg/m2, intravenous) with (group A, 
8 mg/day, orally) or without PX-866 (group B). The 
median PFS was 2 months in group A and 2.9 months in 
group B (p = 0.65); the ORR was 6% and 0% in group 
A and group B, respectively (p = 0.4). There was no 
difference in OS between the two groups (7.0 months 
vs 9.2 months, p = 0.9) [63]. Diarrhea (7%), vomiting 
(7%) and nausea (4%) occurred more in group A, with 
less number of grade 3 or higher adverse events found 
in both two groups [63]. The observations suggest that 
the efficacy of PX-866 is dependent on the treatment 
strategies for NSCLC. 
Pictilisib (GDC-0941)
Pictilisib is an oral class I PI3Ks inhibitor that is 
being evaluated in phase II clinical trials for the treatment 
of breast and NSCLC [64]. Pictilisib has shown good 
safety and tolerability for NSCLC in the phase Ia/Ib 
study: Japanese patients with non-squamous NSCLC or 
advanced solid tumors received pictilisib in monotherapy 
(group A) or in combination with carboplatin-paclitaxel 
and bevacizumab (group B). The dose escalation of 
pictilisib was designed in this study for two stages: 140, 
260, or 340 mg/day of pictilisib was administrated as 
monotherapy (stage 1) and 260 or 340 mg/day of pictilisib 
plus chemotherapy and bevacizumab was administrated 
(stage 2). In stage 1, only grade 3 maculopapular rash 
was found at the dose of 340 mg/day in group A, while an 
objective anti-tumor response was not observed. In stage 2, 
only grade 3 febrile neutropenia occurred at the dose 
of 260 mg/day or 340 mg/day in group B, while partial 
anti-tumor responses were observed in 3 out of 7 patients 
[65]. The efficacy of pictilisib for NSCLC is yet to be 
established in clinical trials.
Buparlisib (BKM120)
Buparlisib is a pan-PI3Ks inhibitor. Buparlisib 
mediated cell growth arrest and apoptosis of NSCLC 
through down-regulating the expression of Mcl-1 [66]. 
It has also been reported that buparlisib up-regulated the 
levels of auto phagosome-bound type II LC3 (LC3-II) 
protein, contributing to autophagy and disappearing of 
NSCLC [66]. However, in the phase II BASALT-1 study: 
63 patients (30 squamous and 33 non-squamous) with 
activated PI3K pathway, metastatic, squamous or non-
squamous NSCLC, who failed previous antineoplastic 
therapies (chemotherapy for squamous or systemic 
antineoplastic for non-squamous) received buparlisib 
(100 mg/day) for 12 weeks. The PFS rate was only 23.3% 
(95% CI = 9.9–42.3) and 20.0% (95% CI = 7.7–38.6) in 
the squamous and non-squamous groups, respectively 
[67], possibly due to overlapping signaling of treatments 
former and latter. Furthermore, both in vitro and in vivo 
studies show that buparlisib plus MEK162 (a MEK 
inhibitor) highly improve therapeutic efficacy against 
the growth of NSCLC cells [68]. Pre-clinical studies 
also showed that buparlisib combined with chloroquine 
inhibited lung cancer cells proliferation and induced 
apoptosis [69]. Combined therapies based on buparlisib 
hold promise for improving the clinical efficacy of patients 
with NSCLC. 
mTOR inhibitors 
Rapamycin binds two proteins (FK- 506 binding 
protein and FKBP-rapamycin-associated protein) as a 
potent immunosuppressive agent to inhibit mTORC1 [70]. 
Rapamycin has many derivatives including sirolimus, 
everolimus, ridaforolimus.
Sirolimus 
Sirolimus is an oral mTOR inhibitor presenting 
unsatisfactory clinical efficacy. In a phase Ib trial, 39 
NSCLC patients with EGFR mutation were randomly 
assigned to afatinib (40 mg/day) plus sirolimus (5 mg/day). 
The PFS was 6 months (33.3%). Adverse events (diarrhea: 
94.9%, mucosal inflammation: 64.1%, asthenia: 53.8% 
and rash: 53.8%) were observed in all patients. Positive 
responses occurred in only 5 patients (12.8%) [71]. The 
results showed the efficacy of afatinib (40 mg/day) plus 
sirolimus was very much limited. 
Everolimus
Everolimus is another novel inhibitor of mTOR 
pathway, yet demonstrating poor relatively clinical 
efficacy of combining with other drugs. In a phase II study, 
28 patients with advanced stage NSCLC that previous had 
chemotherapy were treated with everolimus (5 mg/day) 
and docetaxel (60 mg/m2). The partial response occurred 
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in 2 patients and stable disease was found in 15 patients 
(clinical benefit rate, 70%). The PFS was 6 months and OS 
was 9.6 months in everolimus plus docetaxel treatment. 
The results showed that everolimus plus docetaxel was 
tolerated well without satisfactory efficacy for patients 
with NSCLC [72]. Similarly, in another multicenter, open-
label, phase II study, 133 patients with advanced NSCLC 
that previous had chemotherapy were randomly assigned 
to everolimus (5 mg/day) plus erlotinib (150 mg/day) 
and erlotinib alone. The disease control rate (DCR) at 
3 months in everolimus plus erlotinib group was 39.4% 
and in erlotinib alone group was 28.4%. The median PFS 
was 2.9 months in everolimus plus erlotinib group and 
2.0 months in erlotinib alone group. Grade 3/4 adverse 
events occurred in 72.7% and 32.3% of patients in 
everolimus plus erlotinib group and erlotinib alone group, 
respectively. Grade 3/4 stomatitis was only found in 
combination therapy (31.8%) [73]. These observations 
overall suggest that, everolimus plus erlotinib in 
combination cannot be a novel treatment strategy for 
individuals with NSCLC.
Ridaforolimus
Ridaforolimus is an investigational oral inhibitor 
targeting mTOR pathway. Clinical data showed that 
ridaforolimus is a good choice for patients with advanced 
NSCLC. In a randomized discontinuation phase II trial, 
28 stage IIIB/IV NSCLC patients with KRAS mutation 
were treatment with ridaforolimus (40 mg/day) or placebo. 
The median PFS based on investigator assessment was 
obviously longer in ridaforolimus group (4 months) 
than placebo group (2 months, HR = 0.36, p = 0.013). 
The median OS was 18 months and 5 months in the 
ridaforolimus and placebo group, respectively (HR = 0.46, 
p = 0.09). More than 3 grade adverse events (fatigue: 10%, 
mucositis/stomatitis: 10%, pneumonia: 10%, diarrhea: 6%, 
dyspnea: 9%, and hyperglycemia: 6%) were observed in 
ridaforolimus group [74]. 
ErbB2 amplification and ErbB2 inhibitors
ErbB2 amplification
Human epidermal growth factor receptor 2 (ErbB2, 
HER2), a member of the human EGFR (ErbB) family, 
is a receptor tyrosine kinase and encoded by the HER2 
gene located on the long arm of chromosome 17 (17q21). 
ErbB2 is involved in activation of its downstream 
signaling pathways including PI3K/Akt as well as MEK/
ERK, and necessary for cell proliferation and migration 
[75, 76]. ErbB2 amplification is found in 10–20% of 
NSCLC, while ErbB2 protein over-expression is observed 
in 2.4–38% of NSCLC [77–79].
ErbB2 inhibitors
Neratinib (HKI-272)
Neratinib is an oral, irreversible dual EGFR/HER2 
inhibitor. In vitro, neratinib could inhibit proliferation 
by inducing G1 arrest and apoptotic of lung cancer cells 
[80, 81]. However, clinical data showed that the efficacy 
of neratinib for NSCLC was poor and low efficacy of 
neratinib for NSCLC patients had been observed in a 
phase II trial: NSCLC patients were assigned to group 
A (EGFR mutation, n = 91), group B (wild-type EGFR, 
n = 48), and group C (TKI-naïve, n = 28). All of these 
patients were received neratinib daily. The ORR was 3% 
in group A and zero in both groups B and C. The most 
common toxicity was diarrhea. Obviously, 3 of 4 patients 
with EGFRG719X mutation had a partial response [82]. 
Another phase I study also reported that neratinib plus 
temsirolimus treatment for NSCLC is associated with poor 
efficacy with side effects (diarrhea, nausea and stomatitis) 
[83]. Generally, further study will be needed for neratinib. 
Lapatinib (GW572016)
Lapatinib is an oral, reversible, dual tyrosine 
kinase inhibitor of EGFR and HER2. The clinical 
efficacy of lapatinib monotherapy is uncertainty for 
NSCLC. In a randomized phase II study, patients with 
relapse or metastatic NSCLC were treated with lapatinib 
(1,500 mg/day or 500 mg/bid, orally). There were no 
complete or partial responses in the targeted population 
(n = 56): 25% had stable disease lasting 6 months. No 
responses were observed in patients with EGFR mutations 
(n = 3) and EGFR gene amplification (n = 5). 21% had 
stable disease lasting 6 months and 1.3% had partial 
response of patients in the nontargeted population (n = 
75). Diarrhea, rash, fatigue, nausea, and anorexia were 
the most common adverse events [84]. The combination 
of lapatinib with other agents for treatment of NSCLC 
patients may be tested to improve the efficacy in the 
future.
VEGFR inhibitors
Vascular epidermal growth factor receptor (VEGFR) 
plays an important role in regulating of physiological 
angiogenesis that is closely associated with embryogenesis 
and tumor progress [85]. New blood vessel formation 
(angiogenesis) is required for the process of tumor growth 
and metastatic dissemination. Avascular tumors are 
severely restricted in their growth potential because of the 
lack of a blood supply [86]. Therefore, anti-angiogenesis 
is a valuable new approach to cancer therapy. 
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Bevacizumab
Bevacizumab, a monoclonal antibody against vascular 
endothelial growth factor (VEGF), benefits patients with 
NSCLC. It was applied as the first-line treatment of locally 
advanced, recurrent, unrespectable, or metastatic NSCLC 
in combination with chemotherapy (carboplatin and 
paclitaxel) that was approved by FDA in 2006 [87]. In a 
prospective cohort study, 102 patients with non-squamous 
NSCLC (44.1% of which carried EGFR mutation) received 
bevacizumab (15 mg/kg) with standard chemotherapy. The 
ORR was 44.1%, and the median PFS was 8.3 months in 
bevacizumab with standard chemotherapy (95% CI = 
6.4–10.2). The median OS was 26.3 months (95% CI = 
22.2–30.4). Grade 3-4 hypertension (30.4%) was observed 
in this study [88]. The results of this study showed that bev-
containing chemotherapy was effective and safe for patients 
with non-squamous NSCLC. In another pilot phase II study, 
39 patients with advanced NSCLC were randomly assigned 
to treatment with paclitaxel (80 mg/m2) and gemcitabine (300 
mg/m2, weekly) for 3 weeks, plus bevacizumab (10 mg/kg, 
every two weekly). The median PFS was 8.5 months, the 
ORR was 56% and OS was 25.5 months. Myelosuppressive, 
gastrointestinal or neurologic events were not found in this 
study [89]. In addition, bevacizumab exhibited sufficient 
efficacy and safety for patients with NSCLC who failed first-
line platinum-based chemotherapy: in a randomized phase 
III study, 297 Chinese patients were assigned to two groups: 
bevacizumab plus erlotinib and panitumumab (group A), or 
erlotinib plus placebo (group B). The median PFS in group 
A was much longer than in group B (4.6 months: 95% CI = 
2.3–9.4 vs 1.9 months: 95% CI = 0.8–5.2, p = 0.003). The 
median OS was 10.4 months (95% CI = 7.5–13.1) and 8.9 
months (95% CI = 3.3–10.9) in group A and group B (p = 
0.031), respectively. Partial response in group A was 38%, 
significantly higher than in group B (15%; p = 0.014). In 
addition, diarrhea, fatigue and rash were occurred more 
in group B rather than group A [90]. These observations 
demonstrate that bevacizumab combination with other agents 
may have higher efficacy for patients with NSCLC. 
Sorafenib
Sorafenib is an oral, multi-kinase inhibitor that was 
beneficent for NSCLC. In a multicenter phase II trial, 168 
patients were randomly assigned to sorafenib (400 mg/day, 
bid) plus erlotinib (150 mg/day) or placebo plus erlotinib. 
The median PFS was 3.38 months and 1.94 months in 
sorafenib plus erlotinib and in placebo plus erlotinib, 
respectively (HR = 0.86, 95% CI = 0.60–1.22, p = 0.196). 
The disease control rate was 54% in sorafenib plus erlotinib 
and 38% in placebo plus erlotinib (p = 0.056) [91]. Similar 
clinical efficacy has been showed in another single-arm 
and multicenter phase II trial: 53 patients with advanced 
NSCLC were assigned to sorafenib (800 mg/day). 
The median PFS and median OS were 2.7 months and 
6.7 months, respectively [92]. These results indicate that 
sorafenib monotherapy or combination with other agents 
may be promising for NSCLC treatment.
Sunitinib 
Sunitinib is an oral, multitargeted TKI targeting 
VEGFR, Kit, platelet-derived growth factor (PDGFR), 
FMS-like tyrosine kinase 3 (FLT3) and RET on tumor 
cells, tumor neovasculature and pericytes [93]. Clinical 
trials revealed that sunitinib had a certain extent efficacy 
to NSCLC with some side effects. In a phase III trial, 
960 patients were randomly assigned to sunitinib (37.5 
mg/day) plus erlotinib (150 mg/day) or placebo plus 
erlotinib. The median PFS was 3.6 months in sunitinib 
plus erlotinib versus 2.0 months in erlotinib alone (HR 
= 0.807; 95% CI = 0.695–0.937, p = 0.0023), and ORR 
was 10.6% versus 6.9% in sunitinib plus erlotinib and in 
erlotinib alone (p = 0.0471), respectively. The median 
OS was 9.0 months and 8.5 months in sunitinib plus 
erlotinib and in erlotinib alone, respectively (HR = 
0.922; 95% CI = 0.797–1.067, p = 0.1388). However, 
rash/dermatitis, diarrhea and asthenia/fatigue were 
more frequently observed in the sunitinib plus erlotinib 
group [94]. The same situation happened in another 
randomized, double-blind, placebo-controlled phase 
III study: 210 patients with stage IIIB/IV NSCLC who 
experiencing first-line chemotherapy were randomized 
to receive sunitinib (37.5 mg/day) or placebo. The 
median PFS was 4.3 months in sunitinib and 2.6 
months in placebo (HR = 0.62, 95% CI = 0.47–0.82, p 
= 0.0006). The median OS was 11.7 months in sunitinib 
versus 12.1 months in placebo (HR = 0.98, 95% CI = 
0.73–1.31, p = 0.89). Serious effects including fatigue 
(25%), thrombocytopenia (12%), hypertension (12%) 
and rash (11%) were occurred in sunitinib [95]. These 
results indicate that sunitinib in combination or alone is 
beneficial for advanced NSCLC.
KRAS mutation and KRAS inhibitors
KRAS mutation
In NSCLC, and especially in lung adenocarcinomas, 
signaling of kirsten human rat sarcoma protein (KRAS), a 
main downstream signaling molecule of EGFR pathway, 
is frequently influenced by its own somatic mutations 
[96, 97]. Mutations of EGFR and KRAS are regarded as 
primary genetic “driver” leading to cancer [98]. KRAS 
is frequently activated in NSCLC, and KRAS gene 
mutations were found in 20% of NSCLC. Most KRAS 
mutations reported in NSCLC were found at codon 12 
[97]. Although KRAS mutations were identified in 
lung cancer, there have been very few trials addressing 
NSCLC patients with KRAS mutations, leading to no 
positive therapies [99]. However, there is a dire need for 
therapies specifically for patients with KRAS mutant 
NSCLC.
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KRAS inhibitor
Antroquinonol
Antroquinonol is a small anticancer molecule 
isolated from Antrodia camphorate which shows highly 
anticancer activity [100, 101]. Antroquinonol inhibited Ras 
and Ras-related small GTP-binding protein functions by 
binding directly to farnesyltransferase and geranylgeranyl 
transferase-I (the key enzymes associated with activation 
of Ras-related proteins). Furthermore, antroquinonol 
induced autophagy by increasing the level of light chain 3 
B- II (LC3B-II) and the auto phagosome-associated LC3 
[102]. In an open-label, dose escalation, pharmacokinetic 
(PK) study, 13 patients with metastatic adenocarcinoma 
NSCLC were treated with antroquinonol (escalating doses 
of 50–600 mg/day). No dose-limiting toxicities was seen 
in any patient at any dose level. The mean elimination 
half-life is between 1.30 and 4.33 h, which associates with 
the treatment dose. A mild toxicity profile was observed 
at all dose levels of antroquinonol. Diarrhea, vomiting and 
nausea occurred in this study. The best tumor response was 
stable disease in 3 patients [103]. This study showed that 
antroquinonol was good, safe and tolerated for NSCLC. 
The efficacy of antroquinonol in clinical trials have still 
to be evaluated.
c-MET amplification and c-MET inhibitors 
c-MET amplification
Cellular-mesenchymal to epithelial transition factor 
(c-MET) is a plasma membrane tyrosine kinase activated 
by auto-phosphorylation after ligand binding. The c-MET 
was significantly associated with tumor growth in 
NSCLC [104]. Additionally, a recent study has shown that 
MET amplifications are present in 9 of 43 patients with 
acquired resistance to EGFR TKI (gefitinib and erlotinib) 
[105]. MET amplification was also observed in 4 of 18 
lung cancer patients with gefitinib or erlotinib-resistance 
[106]. These data suggest that MET amplification may 
play an important role in promoting drug resistance. The 
c-MET receptor is an attractive potential target for novel 
therapeutic inhibition in human cancers. 
c-MET inhibitors
Tivantinib
Tivantinib, an oral MET receptor TKI, exhibited 
high anticancer activity in early clinical studies and 
preclinical studies when combined with erlotinib. In 
a phase III multinational, randomized, double-blind, 
placebo-controlled study, 1,048 patients with advanced 
non-squamous NSCLC were randomly assigned to receive 
erlotinib (150 mg/day) plus tivantinib (720 mg/day) or 
erlotinib plus placebo. The median PFS was 3.6 months in 
erlotinib plus tivantinib and 1.9 months in erlotinib alone 
(HR = 0.74, 95% CI = 0.62–0.89, p < 0.001). The median 
OS was 8.5 months versus 7.8 months in erlotinib plus 
tivantinib and in erlotinib alone, respectively (HR = 0.98, 
95% CI = 0.84–1.15, p = 0.81). Diarrhea (34.6% vs 41.0%), 
rash (33.1% vs 37.3%), neutropenia (grade 3 to 4; 8.5% vs 
0.8%) and asthenia or fatigue (43.5% vs 38.1%) were seen 
in both erlotinib plus tivantinib and in erlotinib group [107]. 
Onartuzumab (MP470)
Onartuzumab is a monovalent monoclonal antibody 
targeting MET. Clinical data showed that onartuzumab is 
a good choice for MET-positive patients with NSCLC. 
In a randomized phase II trial, patients with recurrent 
NSCLC were randomly assigned to receive onartuzumab 
plus erlotinib or placebo plus erlotinib [108]. No definite 
conclusion has been derived in PFS (2.2 months vs 
2.6 months; HR = 1.09, p = 0.69) or OS (8.9 months vs 
7.4 months; HR = 0.80, p = 0.34) in the intent-to-
treat (ITT) population (n = 137). However, both PFS 
(2.9 months vs 1.5 months; HR = 0.53, p = 0.04) 
and OS (12.6 months vs 3.8 months; HR = 0.37, p 
= 0.002) were improved for the 66 MET-positive 
(immunohistochemistry diagnostic positive) patients 
that were treated with erlotinib plus onartuzumab. 
Conversely, worse clinical outcomes were occurred in 
62 MET-negative (immunohistochemistry diagnostic 
negative) patients that received onartuzumab plus 
erlotinib (PFS: 1.4 months vs 2.7 months; HR = 1.82, 
p = 0.05; OS: 8.1 months vs 15.3 months; HR = 1.78, 
p = 0.16). Incidence of peripheral edema was observed 
in onartuzumab-treated patients with increased trend 
[108]. Another phase II study showed the same trend 
upon onartuzumab treatment for NSCLC: 109 patients 
with advanced squamous NSCLC were randomly 
assigned to treat with onartuzumab plus chemotherapy 
(paclitaxel plus carboplatin/cisplatin) or placebo plus 
chemotherapy. Similar results were obtained between 
onartuzumab plus chemotherapy and placebo plus 
chemotherapy in term of the risk of disease progression 
or death in ITT (stratified HR = 0.95, 95% CI = 0.63–
1.43) and MET immunohistochemistry diagnostic 
positive (IHC+) populations (unstratified HR = 1.27; 95% 
CI = 0.69–2.32). The grade 3 to 5 adverse events 
(neutropenia and pulmonary embolism) were observed 
14.8% and 5.8% in the onartuzumab plus chemotherapy 
and in the placebo plus chemotherapy, respectively [109]. 
Cabozantinib (XL-184)
Cabozantinib is a multi-kinase inhibitor targeting MET 
and VEGFR2. In a phase II study, patients with NSCLC 
were randomized to treat with cabozantinib alone (100 
mg/day) or cabozantinib (100 mg/day) plus erlotinib 
(50 mg/day). The ORR was 6.7% (90% CI = 0.3–27.9) 
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in the cabozantinib alone (n = 15) with no responses in 
cabozantinib plus erlotinib (n = 13) [110]. There was no 
evidence to show that combination of cabozantinib plus 
erlotinib significantly sensitizes cabozantinib in patients 
with NSCLC.
Su11274
Su11274, the c-MET-specific TKI, in combination 
with EGFR TKIs were used to treat NSCLC cells. One of 
recent studies showed that su11274 potentiated the ability 
of afatinib against EGFRT790M H1975 cells [111]. This 
study has provided evidences that combined inhibition 
of c-MET and EGFR would be a good clinical treatment 
strategy for NSCLC patients. 
PHA-665752
PHA-665752 is a small molecule, inhibitor of 
c-MET kinase. PHA-665752 dramatically suppresses 
Table 1: Targeted therapies for NSCLC
Inhibitor(s) Target(s) Clinical trial (Phase) Reference(s)
Gefitinib EGFR mutation: exon 19 deletions or exon 21 (EGFR L858R) mutations III [34]
Erlotinib EGFR mutation: exon 19 deletions or exon 21 (EGFR L858R) mutations II [40]
Icotinib EGFR mutation: exon 19 deletions or exon 21 (EGFR L858R) mutations III [41]
Afatinib WT EGFR and EGFR mutation: exon 19 deletions or exon 21 (EGFR L858R) mutations III [44, 45]
Dacomitinib WT EGFR and EGFR mutation: exon 19 deletions or exon 21 (EGFR L858R) mutations II, III [49, 50]
Osimertinib EGFR T790M mutation II, III [56]
CT16 EGFR, Notch2/3 - -
PX-866 PI3K II [63]
Pictilisib PI3K I [65]
Buparlisib PI3K II [67]
Sirolimus mTOR I [71]
Everolimus mTOR II [72, 73]
Ridaforolimus mTOR II [74]
Neratinib ErbB2 amplification: the long arm of chromosome 17 (17q21) I, II [82, 83]
Lapatinib EGFR, HER2 II [84]
Bevacizumab VEGFR II, III [89, 90]
sorafenib VEGFR II [91, 92]
sunitinib VEGFR, KIT, PDGFR, FLT3, RET III [94, 95]
Antroquinonol KRAS mutation I [103]
Tivantinib c-MET amplification III [107]
Onartuzumab c-MET amplification II [108, 109]
Cabozantinib c-MET, VEGFR II [110]
Su112749 c-MET amplification - -
PHA-665752 c-MET amplification - -
Crizotinib ALK fusion II, III [123, 124]
Alectinib ALK fusion II [126, 127]
Ceritinib ALK fusion II [128, 129]
Dabrafenib BRAF V600E II [136, 137]
Molecular targets, corresponding inhibitors and clinical trials are included. 
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tumor growth, as well as angiogenesis, in mouse NCI-H441 
xenografts model [112]. The study suggested that PHA-
665752 may be a novel inhibitor of lung cancer. Additional 
clinical trials of PHA-665752 for NSCLC are required in 
the future.
ALK fusion and ALK inhibitors 
ALK fusion
Anaplastic lymphoma kinase (ALK), a tyrosine kinase 
receptor, was found in anaplastic large-cell lymphoma 
(ALCL) cell lines in 1994 as a member of the insulin receptor 
superfamily which was closely associated with both solid 
and hematological tumors [113]. ALK gene rearrangements 
have described in NSCLC. The echinoderm microtubule-
associated protein-like 4 gene and the anaplastic lymphoma 
kinase gene (EML4-ALK) fusion oncogene was identified 
as a novel effective target in NSCLC in 2007 which has 
been detected in 5% NSCLC patients [114–116]. EML4-
ALK fusions have been manifested to be mutually exclusive 
with EGFR or KRAS mutation found in patients without 
smoking history [117, 118]. However, drug resistance has 
been identified for crizotinib which was contributed by 
secondary mutations and therefore activation of either a 
bypass signal pathway (KIT or EGFR), or the ALK gene 
itself (such as F1174L, L1196M, C1156Y, G1269A, S1206Y, 
and G1202R), or gene amplification [119, 120].
ALK inhibitors
Crizotinib
Crizotinib, as a first generation ALK tyrosine kinase 
inhibitor, has been approved by US FDA in 2014 [121]. 
Crizotinib showed highly efficacy in NSCLC patient 
with ALK rearrangements, targeting ALK, MET, ROS1 
[122]. In a single-arm, open-label, phase I–II study, 
Table 2: Results of clinical trails
Inhibitor Subjects(N)
PFS OS ORR
Time
(month)
p-
value
95% 
CI
Time
(month)
p-
value
95% 
CI
Rate
(%)
p-
value
95% 
CI
Gefitinib 261 10.9 0.001 0.4–0.8 - - - 67.0 0.0004 1.6–5.5
Erlotinib 154 16.0 0.002 13.9–18.1 - - - - - -
Icotinib 400 4.6 0.1 3.5–6.3 13.3 - 11.1–16.2 62.1 0.5 0.5–3.8
Afatinib 910 11.0 <0.0001 9.7–13.7 22.1 0.8 20.0-not estimable
66.9 <0.0001 4.3–12.2
Dacomitinib 121 14.6 0.2 9.0–18.2 26.6 - 20.1–29.0 62.1 - 0.5–0.7
Osimertinib ongoing ongoing ongoing ongoing ongoing ongoing ongoing ongoing ongoing ongoing
PX-866 95 2.0 0.7 - 7.0 0.9 - 6.0 0.4 -
Buparlisib 63 3.0 - 9.9–42.3 8.0 - 6.0–10.1 3.3 - 0.1–7.2
Sirolimus 39 3.4 - 1.8–6.3 - - - - - -
Everolimus 133 2.9 0.2 2.4–3.9 9.1 - 7.5–11.1 - - -
Ridaforolimus 28 4.0 0.01 - 18.0 0.09 - - - -
Neratinib 167 15.3 - 14.7–15.9 - - - - - -
Lapatinib 75 3.7 - - 14.5 - - - - -
Bevacizumab 297 4.6 0.003 2.3–9.4 10.4 0.03 7.5–13.1 38.0 0.01 -
sorafenib 168 3.4 0.2 0.6–1.2 6.7 8.0 0.19 8.0 0.6 -
sunitinib 960 3.6 0.002 0.7–0.9 9.0 0.2 0.8–1.1 10.6 0.05 -
Tivantinib 1048 3.6 0.001 0.6–0.9 8.5 0.8 0.8–1.2 - - -
Onartuzumab 137 2.9 0.04 - 12.6 0.002 - 5.8 - -
Cabozantinib 65 3.9 - 1.5–7.3 - - - 6.7 - 0.3–27.9
Crizotinib 343 10.9 <0.001 0.4–0.6 17.4 0.4 0.5–1.3 74.0 <0.001 -
Alectinib 87 8.1 - 6.2–11.6 12.0 - 61.0–88.0 48.0 - 0.4–0.6
Ceritinib 140 5.7 - 5.4–7.6 14.9 - 13.5–not estimable
38.6 - 0.3–0.5
Dabrafenib 84 5.5 - 3.4–7.3 12.7 - 7.3–16.9 33.0 - 0.2–0.5
The results of molecular target inhibitors of NSCLC are summarized including PFS, OS and ORR.
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NSCLC patients harboring ALK rearrangements (phase 
I, n = 24; phase II, n = 46) were given crizotinib (phase 
I, 20–300 mg/bid; phase II, 300 mg/bid). In Phase I, no 
adverse events of grade 4 were founded up to the highest 
dose. In Phase II, the objective response rate was 93.5% 
(n = 43, 95% CI = 82.1–98.6). Adverse events of grade 3 
were noted in 12 of 46 patients, and no grade 4 adverse 
events or deaths were recorded [123]. In another phase 
3 trial, 343 patients with advanced ALK-positive non-
squamous NSCLC were randomly assigned to receive 
crizotinib (250 mg/bid) or chemotherapy (pemetrexed 
or plus either cisplatin, or carboplatin). The median 
PFS was significantly longer in crizotinib group than 
in chemotherapy group (10.9 months vs. 7.0 months, 
HR = 0.45, 95% CI = 0.35–0.60; p < 0.001). Patients in 
crizotinib group showed highly reduction in lung cancer 
symptoms and better improvement in quality of life [124].
Alectinib
Alectinib, as a second-generation highly selective 
small-molecule ALK inhibitors, shows great efficacy for 
overcoming crizotinib resistance in NSCLC patients with 
ALK rearrangements [125]. In a phase II study, 87 patients 
had received prior crizotinib therapy were randomly 
assigned to receive alectinib. The ORR was 48% (95% 
CI = 0.36–0.60). Grade 1 or 2 adverse events (peripheral 
edema, myalgia, fatigue and constipation) were observed 
in this study [126]. Alectinib also showed effective in the 
3-year follow-up of phase II: patients with ALK positive 
NSCLC received alectinib (300 mg//bid). The 3-year PFS 
rate was 62% (95% CI = 45–75) and OS rate was 78% 
[127]. 
Ceritinib
Ceritinib is another ALK inhibitor which has been 
approved by FDA in 2014. It shows great clinical efficacy 
against crizotinib-resistant ALK-positive tumors. In a 
Multicenter Phase II Study, 140 patients with advanced 
ALK-rearranged NSCLC who had been previously treated 
with crizotinib were randomly assigned to given ceritinib. 
The median PFS was 5.7 months (95% CI = 5.4–7.6), the 
overall response rate was 38.6% (95% CI = 0.30–0.47) 
and disease control rate was 77.1% (95% CI = 0.69–0.84) 
[128]. In another Open-Label, Multicenter, Phase II Study, 
32 patients with advanced ALK-positive NSCLC were 
randomly assigned to receive ceritinib (750 mg/day). 
The median PFS and median OS were 9.3 months (95% 
CI = 0–22) and 24 months (95% CI = 5–43), respectively. 
The ORR was 62% (95% CI = 0.45–0.77) and the duration 
of response was 21.0 months (95% CI = 17–25); DCR was 
81% (95% CI= 0.65–0.91) [129]. 
BRAF mutation and BRAF inhibitor
BRAF mutation
vRaf murine sarcoma viral oncogene homolog B 
(BRAF), as a proto-oncogene, encodes a serine/threonine 
protein kinase that promotes cell survival and proliferation 
[130]. BRAF mutations have been identified in a wide 
range of malignancies including 10% of colorectal 
carcinoma [131], and 50% of malignant melanomas [132]. 
The BRAF Val600Glu (V600E) mutation were commonly 
seen in BRAF mutations that had been mainly found 
approximately 90% of melanoma [133]. The frequency of 
BRAF V600E mutation in NSCLC is about 1%–3% [134].
BRAF inhibitor
Dabrafenib (GSK2118436)
Dabrafenib, as an oral selective BRAF inhibitor 
[135]. Dabrafenib has shown activity in patients with 
advanced NSCLC harboring the BRAF V600E mutation. In 
a phase II study, 84 advanced NSCLC patients with BRAF 
V600E mutation were treated with dabrafenib (150 mg/bid). 
The median PFS of this study was 5.5 months (95% 
CI = 3.4–7.3) and the ORR was 33% (95% CI = 0.23–0.45). 
The median OS was 12.7 months (95% CI = 7.3–16.9) 
[136]. However, combining dabrafenib with trametinib 
(a MEK inhibitor) may reveal a more effective treatment 
strategy. In an open-label, phase II trial, 36 advanced 
NSCLC patients with BRAF V600E mutation patients were 
randomly assigned to receive dabrafenib plus trametinib. 
The median OS was 24.6 months (95% CI = 12.3–not 
estimable) and the ORR was 64% [137]. 
CONCLUSIONS AND PERSPECTIVES 
Recently, a series of achievements have been made 
in NSCLC treatment with the better understanding of the 
molecular biology of NSCLC. Molecular targeted therapy 
based on targeting specificity can improve treatment 
safety and efficiency for NSCLC patients (Tables 1 and 2), 
although there are still challenges in development and 
application of targeted drugs. First of all, the efficacy 
of targeted drugs is yet to be improved alone with the 
potential side effects of the drugs; secondly, effective drug 
combinations hold promise and await further development. 
Furthermore, acquired resistance needs to be dealt with 
great efforts due to the constant occurrence after targeted 
therapies. With concerted efforts in these fields, the 
ultimate goal of achieving effective and harmless NSCLC 
therapy may be achievable.
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Ratio; CI: Confidence interval; TKI: Tyrosine kinase 
inhibitor; FDA: Food and Drug Administration; DoR: 
Duration of response; IPASS: Iressa Pan-ASia Study; 
ITT: Intent-to-treat; OR: Odds ratio; ORR: Objective 
response rate; US: United States; CFDA: China Food and 
Drug Administration; MEK: Mitogen-activated protein 
kinase; DCR: Disease control rate; MAPK10: Mitogen 
activated protein kinase 10; PIM-1: Polymer of intrinsic 
microporosity; DHODH: Dihydroorotate dehydrogenase; 
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17β Hydroxysteroid dehydrogenase type 1; CHK2: 
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ERK: Extracellular Signal-regulated Kinase; RAF: 
Rapidly accelerated fibrosarcoma; JAK: Janus kinase; 
Shc: Generic shell script compiler; Src: Steroid receptor 
coactivator; GSK-3: Glycogen synthase kinase 3; Bmi: 
Body mass index; STAT3: Signal transducer and activator 
of transcription 3; DNA: Deoxyribonucleic acid; RNA: 
Ribonucleic acid; PDGFR: Platelet-derived growth 
factor; FLT3: Fms-like tyrosine kinase 3; ALK-anaplastic 
lymphoma kinase; BRAF-V-Raf murine sarcoma viral 
oncogene homolog B.
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